

7. (Amended) The vector of claim 5, wherein the polypeptide is a fusion polypeptide comprising an amino acid sequence of EBNA-1 and a heterologous amino acid sequence.

8. (Amended) The vector of claim 5 which is a viral vector.

Please add new claims 20-34 as follows:

20. (New) A pharmaceutical composition comprising an EBNA-1 charged dendritic cell and a pharmaceutically acceptable carrier.

21. (New) The pharmaceutical composition of claim 20 further comprising a cytokine.

22. (New) A pharmaceutical composition comprising an EBNA-1 charged dendritic cell and a pharmaceutically acceptable carrier, wherein the EBNA-1 charged dendritic cell is prepared according to the method of introducing an EBNA-1 antigen into the dendritic cell, which EBNA-1 antigen is processed and presented on the surface of the dendritic cell, whereby the dendritic cell activates T cells.

23. (New) The pharmaceutical composition of claim 22 wherein introducing EBNA-1 antigen into the dendritic cell comprises contacting the dendritic cell with a viral vector encoding the EBNA-1 antigen.

24. (New) The pharmaceutical composition of claim 22 wherein introducing EBNA-1 antigen into the dendritic cell comprises contacting the dendritic cells with exogenous EBNA-1 polypeptide.

25. (New) The pharmaceutical composition of claim 22 wherein the dendritic cell undergoes maturation prior to introducing the EBNA-1 antigen.

26. (New) The pharmaceutical composition of claim 22 wherein the dendritic cell undergoes maturation following introducing the EBNA-1 antigen.

27. (New) A method for protecting a subject from infection by Epstein Barr Virus, which method comprises administering an EBNA-1 charged dendritic cell to a subject in need of such protection.

28. (New) A method for protecting a subject from Epstein Barr Virus-associated malignancies, which method comprises administering an EBNA-1 charged dendritic cell to a subject in need of such protection.

29. (New) The method of claim 28 wherein the malignancy is nasopharyngeal cancer.

62  
30. (New) The method of claim 28 wherein the malignancy is selected from the group consisting of Burkitt's lymphoma, Hodgkin's lymphoma, T cell lymphoma, gastric cancer and uterine leiomyosarcoma.

31. (New) A method for protecting a subject against Epstein Barr Virus-associated diseases, which method comprises administering an EBNA-1 charged dendritic cell to a subject in need of such protection.

32. (New) The method of claim 31 wherein the Epstein Barr-associated disease is selected from the group consisting of infectious mononucleosis, lymphoproliferative diseases, and chronic fatigue syndrome.

33. (New) A method for protecting a subject against Epstein Barr-associated malignancies, which method comprises:

contacting a dendritic cell with EBNA-1 *ex vivo* and

administering the EBNA-1 contacted dendritic cell to a subject in need of such protection.

34. (New) A method for protecting a subject against Epstein Barr-associated diseases comprising:

contacting a dendritic cell with EBNA-1 *ex vivo* and

administering the EBNA-1 contacted dendritic cell to a subject in need of such protection.

#### **REMARKS**

No new subject matter has been incorporated into the application as a result of this amendment. This submission is accompanied by a mark-up copy of the amended claims.

Claims 6-8 have been amended to correct clerical errors.

The newly added claims find support in the claims and specification as originally filed. For example, page 33, lines 16-30 support introduction of antigen into dendritic cells, presentation of the antigen by dendritic cells, and stimulation of T cells by antigen presented by dendritic cells, and page 11, lines 2-4 describe immunotherapy using EBNA-1 charged dendritic cells.

Further examples of support for the new claims are as follows. Support for new claim 20 can be found at page 31, lines 28-30, page 32, lines 1-9. Support for new claim 21 can be found at page 31, lines 13-27; support for new claim 22 can be found at page 39, lines 22-30 and page 40, lines 1-17. Support for new claims 23 and 24 can be found at page 42, lines 16-17. Support for new claim 25 can be found at page 32, lines 28-29. Support for new claim 26 can be